Disease mongering: turning ordinary life into treatable illness
Disease mongering is the practice of widening the boundaries of illness, or inventing new conditions outright, in order to expand the market for treatment. The term describes how ordinary life, normal human variation, and mere risk factors are reframed as medical problems that call for diagnosis, monitoring, and usually a product. It does not claim that serious diseases are imaginary or that medicine is a fraud. It is a specific criticism about where a boundary gets drawn, who draws it, and whose interests that placement serves.
This page is an independent reference on the concept. It is not connected to the 2006 conference in Newcastle, Australia that helped popularize the phrase, to that event’s organizers, or to any earlier owner of this domain. Nothing here is medical advice: it examines the marketing, definitions, and scholarly debate around health labels, and never tells any reader whether a condition applies to them.
The meaning of disease mongering
The writer Lynn Payer coined the phrase in her 1992 book Disease-Mongers: How Doctors, Drug Companies, and Insurers Are Making You Feel Sick. She argued that a loose alliance of interests benefits when more people believe they are sick, and she catalogued the persuasion techniques that push in that direction. A decade later the idea reached a wider audience through the journalists and researchers Ray Moynihan and Alan Cassels, whose book Selling Sickness (2005) framed the same phenomenon as an industrial process: profitable diseases can, in effect, be built and sold.
Readers searching in other languages will find the concept discussed under translated labels, and the English term is often kept untranslated as a technical phrase. What matters is not the wording but the underlying claim: that the line between healthy and sick is not fixed by nature alone. It is negotiated, and commercial pressure can move it. Because “disease mongering” carries a built-in accusation, careful writers use it to describe a pattern of incentives and evidence, not to smear any single company or clinician.
Disease versus illness: why the boundary is contested
Part of the debate turns on an old distinction between disease and illness. In common usage the two words are interchangeable, but in medicine and sociology they point at different things. A disease is a defined biological abnormality, usually marked by an agreed cutoff such as a blood-pressure number, a blood-sugar reading, or a bone-density score. An illness is the lived experience of feeling unwell. The two do not always line up. A person can have a disease label and feel completely fine, and a person can feel genuinely unwell without meeting any diagnostic threshold.
Disease mongering exploits the gap between them in two directions. It can take a normal experience that causes mild distress, shyness, sadness after a loss, a restless night, and attach a disease name to it. It can also take a laboratory number that predicts future risk and treat that number itself as a present illness. In both moves, something that was once part of the range of ordinary life is redrawn as a condition to be managed.
How ordinary life becomes a treatable illness
The reclassification tends to follow a recognizable sequence rather than a single dramatic step. A committee lowers a diagnostic threshold, so millions of people who were “normal” yesterday become patients today. A vague cluster of complaints receives a crisp clinical name and an acronym, which makes it feel established. A risk factor such as blood pressure, cholesterol, or bone thinning is renamed with a disease-like label so that the risk becomes the diagnosis. Awareness campaigns, often funded by a company that sells the relevant product, teach the public to notice symptoms and ask a doctor about them. These moves are laid out in detail in The tactics of disease mongering, which treats them as a repeatable playbook.
None of these steps is automatically wrong. Lowering a threshold can be sound medicine when strong evidence shows that earlier treatment prevents real harm. The criticism arises when the evidence is thin, when the people setting the threshold have financial ties to the treatment, or when the harms of labeling and medicating large healthy populations are left out of the conversation.
Widely cited examples
The literature returns again and again to a familiar set of cases. Each involves a real spectrum of human experience whose treatable portion was expanded, sometimes reasonably and sometimes past what the evidence supports.
| Case | How the boundary widened |
|---|---|
| Low testosterone (“Low T”) | Ordinary tiredness and lower libido in aging men reframed as a hormone deficiency needing gels and injections. |
| Social anxiety disorder | Common shyness and stage fright presented as a chronic condition treatable with antidepressants. |
| Prehypertension and prediabetes | Below-threshold laboratory numbers renamed as near-disease states, enlarging the treated population. |
| Osteopenia | Below-average but not diseased bone density turned into a target for long-term medication. |
| Restless legs syndrome | A real but often mild sensation promoted, through drug marketing, as a widespread disorder. |
A fuller set is examined on the examples page, which handles each case fairly and notes where the underlying condition is undeniably real. The point of the list is never that these labels are fake. It is that the size of the treated group, and the certainty with which mild cases are told they need lifelong therapy, are shaped by marketing as much as by biology.
Disease mongering and drug marketing
The pharmaceutical industry is central to the debate because a widened disease boundary translates directly into more customers. Marketing rarely says “take this product.” More often it sells the diagnosis: it teaches people to interpret an everyday feeling as a symptom, supplies a checklist, and directs them to a clinician who can prescribe. In countries that permit direct-to-consumer advertising, this messaging reaches patients before they ever see a doctor. Industry funding also flows to patient groups, medical education, and the specialists who sit on the panels that define conditions, which is why critics focus on disclosed conflicts of interest rather than on hidden conspiracies.
Balance matters here. Medicalization, the broader process of bringing human experiences under medical authority, has produced enormous good: it has legitimized suffering that was once dismissed, opened access to effective treatment, and reduced stigma around conditions such as depression and addiction. The disease-mongering critique does not reject that history. It asks a narrower question about the margins, where the benefit of an additional diagnosis is small and the costs of overtreatment, anxiety, and wasted resources are real.
How this reference is organized
The material here is arranged so that a newcomer can move from definition to mechanism to evidence. A plain-language entry, What is disease mongering?, gives the shortest self-contained answer. The tactics page dissects the playbook step by step. The examples page walks through the widely cited cases. A separate history of Selling Sickness traces the idea from Lynn Payer through Moynihan and Cassels and the 2006 PLoS Medicine collection, and a neutral account of the Newcastle conference explains where the term entered wide circulation. Read together, they support a simple aim: to help readers tell the difference between medicine that finds disease and marketing that manufactures it.